These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 23135762)

  • 1. Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.
    Watanabe T; Sugauchi F; Tanaka Y; Matsuura K; Yatsuhashi H; Murakami S; Iijima S; Iio E; Sugiyama M; Shimada T; Kakuni M; Kohara M; Mizokami M
    Gut; 2013 Sep; 62(9):1340-6. PubMed ID: 23135762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.
    Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Iio S; Oshita M; Hagiwara H; Mita E; Inui Y; Hijioka T; Inada M; Tamura S; Yoshihara H; Inoue A; Imai Y; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Hayashi N; Takehara T
    J Gastroenterol; 2014 Apr; 49(4):737-47. PubMed ID: 23689988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
    Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
    World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.
    Toyoda H; Kumada T; Hayashi K; Honda T; Katano Y; Goto H; Kawaguchi T; Murakami Y; Matsuda F
    J Med Virol; 2011 Sep; 83(9):1559-64. PubMed ID: 21739446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms.
    Akkarathamrongsin S; Payungporn S; Thong VD; Poovorawan K; Prapunwattana P; Poovorawan Y; Tangkijvanich P
    World J Gastroenterol; 2014 Aug; 20(30):10599-605. PubMed ID: 25132781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
    Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Tada T; Kawaguchi T; Murakami Y; Matsuda F
    J Med Virol; 2011 Jul; 83(7):1203-11. PubMed ID: 21567424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
    Hayes CN; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Imamura M; Ochi H; Kamatani N; Nakamura Y; Chayama K
    Gut; 2011 Feb; 60(2):261-7. PubMed ID: 21068134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.
    Naggie S; Osinusi A; Katsounas A; Lempicki R; Herrmann E; Thompson AJ; Clark PJ; Patel K; Muir AJ; McHutchison JG; Schlaak JF; Trippler M; Shivakumar B; Masur H; Polis MA; Kottilil S
    Hepatology; 2012 Aug; 56(2):444-54. PubMed ID: 22331604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
    Moghaddam A; Melum E; Reinton N; Ring-Larsen H; Verbaan H; Bjøro K; Dalgard O
    Hepatology; 2011 Mar; 53(3):746-54. PubMed ID: 21374656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.
    Hsu CS; Hsu SJ; Chen HC; Tseng TC; Liu CH; Niu WF; Jeng J; Liu CJ; Lai MY; Chen PJ; Kao JH; Chen DS
    Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3719-24. PubMed ID: 21321200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
    Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
    AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1.
    Amanzada A; Schneider S; Moriconi F; Lindhorst A; Suermann T; van Thiel DH; Mihm S; Ramadori G
    J Med Virol; 2012 Aug; 84(8):1208-16. PubMed ID: 22711348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.
    Kawaoka T; Takahashi S; Takaki S; Hiramatsu A; Waki K; Hiraga N; Miki D; Tsuge M; Imamura M; Kawakami Y; Aikata H; Ochi H; Onoe T; Tashiro H; Ohdan H; Chayama K
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1467-72. PubMed ID: 22432893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.
    Fukuhara T; Taketomi A; Motomura T; Okano S; Ninomiya A; Abe T; Uchiyama H; Soejima Y; Shirabe K; Matsuura Y; Maehara Y
    Gastroenterology; 2010 Nov; 139(5):1577-85, 1585.e1-3. PubMed ID: 20708617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
    Boglione L; Cusato J; Allegra S; Cariti G; Di Perri G; D'Avolio A
    Arch Virol; 2015 Aug; 160(8):2009-17. PubMed ID: 26060059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.
    Jia Z; Ding Y; Tian S; Niu J; Jiang J
    PLoS One; 2012; 7(9):e45698. PubMed ID: 23029188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
    Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
    Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.